Where Should Big Gifts Go?
National Charities or University-Based Research & What “Preeminent Generosity” Recommends
Image: Adobe Stock generated with AI by Venom
Every serious donor eventually confronts a version of the same question. Should we broadly donate to trusted national organizations like the American Heart Association or the American Cancer Society, or should we direct capital to university-based medical research, where discoveries are made?
It is a fair question. It is also a consequential one.
Because behind this question sits a deeper issue. What kind of impact are we trying to achieve and over what time horizon?
The Case for National Charities
Organizations like the American Heart Association (AHA) and the American Cancer Society (ACS) have built something that is not easily replicated: National platforms of trust, scale, and reach.
They do several things exceptionally well.
They fund research, often as early-stage seed capital that later grows into major scientific breakthroughs. Many National Institutes of Health (NIH)-funded investigators began with grants from organizations such as the AHA and the ACS.
They translate into practice – developing guidelines, prevention strategies, and public education campaigns that reach millions of people.
They advocate for policy change shaping legislation, insurance coverage, and public health priorities.
They also engage the public. Walks, campaigns, and community events are not merely fundraising mechanisms. They are awareness engines that influence behavior at scale.
From a generosity standpoint, these institutions are not just funders. They are the connective tissue between science and society.
The Critique: Cost, Complexity, and Diffusion
And yet, serious donors often hesitate.
The concern is not the mission. It is structure.
Large national charities must maintain:
Fundraising operations.
Marketing platforms.
National offices.
Community programs.
All of which require resources. Considerable resources.
The metric often cited is cost-to-raise-a-dollar – how much it costs an organization to generate one dollar of philanthropic revenue.
Charity watchdogs like Charity Navigator and Candid generally show that large national charities operate within acceptable efficiency ranges, often spending roughly $0.15 to $0.25 per dollar raised, depending on the year and the campaign mix.
That is not inefficient, but it is not negligible.
By comparison, a direct gift to a university medical center or research lab:
Has little or no fundraising overhead attached to that specific gift.
Can be deployed directly into research, equipment, or faculty support.
For donors focused purely on capital efficiency, that difference matters.
The Case for University-Based Research
Universities and academic medical centers are where most breakthrough discoveries actually occur.
They offer:
Direct access to principal investigators.
Opportunities for endowed chairs and research programs.
Infrastructure for clinical trials and translational science.
Naming-level investments tied to long-term discovery.
A major or principal gift to a university can:
Accelerate a specific line of research.
Recruit top-tier scientific talent.
Build facilities that support decades of innovation.
From a Generosity perspective, this is capital architecture at its highest level, placing resources directly into the engines of discovery.
The Risk of Going Too Narrow
But there is a counterpoint.
University-based giving can be:
Highly specialized.
Long-horizon.
Uncertain in outcome.
A breakthrough may take decades or may never arrive.
And even when discoveries are made, they still require:
Dissemination.
Public adoption.
Clinical standardization.
This is precisely where organizations like AHA and ACS excel.
In other words, universities discover, but national charities distribute.
The Track Record Question
So, which has been more impactful?
The honest answer is both – and often together.
Many advances in cardiovascular care and oncology have followed a familiar path:
Early-stage funding from organizations like AHA or ACS.
Expanded research through universities and NIH.
Clinical validation through academic medical centers.
Broad dissemination through national organizations.
The system is interdependent.
Trying to isolate one part as “more impactful” misses how progress actually happens.
Cost-to-Raise vs. Cost-to-Solve
This is where the conversation goes off track.
Donors focus on cost-to-raise-a-dollar.
But the more important metric may be cost-to-solve-a-problem.
A dollar spent on fundraising is not inherently wasteful if it enables:
Larger pools of capital.
Greater awareness.
Behavioral change at scale.
At the same time, a dollar placed directly into research is not inherently efficient if:
It lacks a pathway to implementation.
It remains isolated within a lab.
Preeminent philanthropy requires evaluating both.
A More Sophisticated Approach
Rather than choosing one model over the other, the more effective strategy may be to integrate them.
Anchor in Research | Direct significant capital to university-based programs, principal investigators, and translational research initiatives. This supports discovery and long-term advancement.
Support the Platforms of Scale | Continue to fund national organizations like AHA and ACS, their public education and advocacy work, and their ability to translate science into practice. This ensures discoveries reach people.
Build Bridges Between the Two | This is where the opportunity lies. Donors can fund collaborative programs between universities and national charities, support clinical translation initiatives, and invest in dissemination strategies that bring research into communities. This is, in effect, a public-private-philanthropic partnership within medicine itself.
The Generosity Perspective
The question is not whether to support national charities or universities.
The question is: how do we design a philanthropic system in which discovery, translation, and access reinforce one another?
Preeminent Generosity is not about choosing sides. It is about building structure:
Universities provide the science.
National charities provide the reach.
Philanthropy provides the capital that connects them.
Shaping How Progress Happens
If you are making a $10,000 gift, the decision may be – should be – personal.
If you are making a $10 million gift, the decision should be architectural in nature.
Because at that level, you are not just funding a program. You are shaping how progress happens.
And the most effective donors – the ones who change outcomes – are those who understand that generosity is not only about where money goes. It is about how the system works.
